NeurologyLive® Friday 5 — December 22, 2023

News
Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 22, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Neurostimulation and Targeted Treatment Delivery in Epilepsy Care: Martha Morrell, MD

The clinical professor of neurology at Stanford University School of Medicine talked about the collaboration of Rapport leveraging NeuroPace’s data analysis capabilities to study the target delivery of a therapy for focal epilepsy. [WATCH TIME: 5 minutes]

Neurostimulation and Targeted Treatment Delivery in Epilepsy Care: Martha Morrell, MD

2: IJMSC Insights: Kenneth Pakenham on MS Care Partner Research

A new feature on NeurologyLive®, IJMSC Insights offers a closer look at the latest research and the people behind it from the community of the International Journal of Multiple Sclerosis Care (IJMSC) and the Consortium of Multiple Sclerosis Centers (CMSC).

 IJMSC Insights: Kenneth Pakenham on MS Care Partner Research

3: Understanding Stathmin-2’s Impact on ALS Motor and Sensory Denervation: Cathleen M. Lutz, PhD

The vice president of the Rare Disease Translational Center at the Jackson Laboratory discussed results from a recently published study reinforcing stathmin-2 as a potential therapeutic strategy for ALS. [WATCH TIME: 4 minutes]

 Understanding Stathmin-2’s Impact on ALS Motor and Sensory Denervation: Cathleen M. Lutz, PhD

4: NeurologyLive Insights: The Future of HD Treatment

Daniel Claassen, MD, MS, reviews emerging treatment options for HD, and shares resources for patients, caregivers, and physicians to navigate diagnosis and management of HD.

The Future of HD Treatment

5: ACTRIMS: High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis

Jason Freeman, MD, MBA, and Abby Rogers, DMSc, PA-C, MPAS, discuss a study presented at ACTRIMS 2023 on high-efficacy disease-modifying therapies for treatment-naïve patients with multiple sclerosis. Sponsored by Novartis.

 High-Efficacy Disease-Modifying Therapies for Multiple Sclerosis
Related Videos
A panel of 3 experts on Alzheimer's disease
A panel of 3 experts on Alzheimer's disease
Christos Papadelis, PhD
Ro'ee Gilron, PhD
Monica Verduzco-Gutierrez, MD
Shahid Nimjee, MD, PhD
Peter J. McAllister, MD, FAAN
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.